Medivir AB stock analysis
Medivir AB (0GP7) Share Price & Analysis
0GP7 Stock Chart & Stats
- Day’s Range
- SEK 1.07 - SEK 1.12
- 52-Week Range
- SEK 0.40 - SEK 2.88
- Previous Close
- SEK 1.12
- Volume
- N/A
- Average Volume (3M)
- 4,831
- Market Cap
- SEK 699.08M
- Enterprise Value
- SEK 778.76M
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.35
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Medivir AB News
0GP7 FAQ
What was Medivir AB’s price range in the past 12 months?
What is Medivir AB’s market cap?
When is Medivir AB’s upcoming earnings report date?
How were Medivir AB’s earnings last quarter?
Is Medivir AB overvalued?
Does Medivir AB pay dividends?
What is Medivir AB’s EPS estimate?
How many shares outstanding does Medivir AB have?
What happened to Medivir AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medivir AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Medivir AB
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jens Lindberg
- Employees
- 7
- Website
- www.medivir.com
- Address
- Lunastigen 5, Huddinge, AB, 14122, SE
Medivir AB (0GP7) Earnings & Revenues
0GP7 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with management highlighting full funding for three phase II studies through at least 2030, on-plan progress in FLEX-HCC and MIV-711, strengthened fostrox intellectual property, and advancement of all three out-licensed programs. The main negatives were lower royalty revenue, a wider operating loss, higher clinical-study costs, negative operating cash flow, and a relatively quiet news flow. Overall, the operational and financial runway highlights significantly outweighed the stated challenges.
View all GB:0GP7 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 0 | 16 |
| Technical Analysis | 6 | 0 | 4 |
| Moving Averages | 0 | 0 | 12 |







